OMass Therapeutics
PrivateLast Round
Series B
Extension
May 15, 2023
Est. Valuation
$498M
Total Funding Raised
$166.1M
Company Overview
OMass Therapeutics is a biotechnology company that discovers and develops novel small molecule medicines for rare diseases and immunological conditions using its proprietary structural mass spectrometry technology platform.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OMass Therapeutics Comparables
Compare OMass Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Confo Therapeutics | 79% | |
| HotSpot Therapeutics | 78% | |
| Frontier Medicines | 78% |
OMass Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 15, 2023 | ||||
| Series B | Apr 28, 2022 | ||||
| Series A Extension | Feb 17, 2020 | ||||
| Series A | Nov 20, 2018 |
OMass Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series B Extension, Series B |
| Syncona | Series B, Series B Extension, Series A Extension, Series A |
| Oxford Science Enterprises | Series A Extension, Series B, Series B Extension, Series A |
| British Patient Capital | Series B Extension |
| Northpond Ventures | Series B Extension, Series B |
| University of Oxford | Series A Extension, Series B |
| Sanofi Ventures | Series B Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
Company faces lawsuit over intellectual property dispute.
- Jan 28, 2026
Jonathan Montagu appointed as new Board Chair.
OMass Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about OMass Therapeutics's valuation, stock price, and market status.
Is OMass Therapeutics a public or private company?
OMass Therapeutics is a private company.
What is the current stock price of OMass Therapeutics?
OMass Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is OMass Therapeutics worth (valuation)?
Valuation information for OMass Therapeutics is not publicly available.
Can I buy OMass Therapeutics stock?
OMass Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was OMass Therapeutics's last funding round?
OMass Therapeutics's most recent funding round was Series B Extension on May 15, 2023.
Who are the main investors in OMass Therapeutics?
Key investors in OMass Therapeutics include GV, Syncona, Northpond Ventures, Sanofi Ventures.
Will OMass Therapeutics IPO soon?
No public IPO plans have been announced for OMass Therapeutics.
How can I track OMass Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OMass Therapeutics's secondary market activity and sign up for updates.